One of its advanced projects targets CD70, an antigen overexpressed across multiple tumour types, but otherwise rarely found in the body. The first-in-human trial of this therapy for patients with ...

In the lab, the team also showed that engineered immune cells — chimeric antigen receptor (CAR) T cells and natural killer cells — could target CD70 on tumour cells. “It’s certainly ...

Other ADCs directed against other B-cell lineage antigens, including CD22, CD19 and CD70, are currently in Phase I/Phase II clinical trials. Early clinical data are encouraging. Important ...

After encountering antigen in the periphery and under the influence ... Epigenetic modification of the CD70 and CD40 ligand promoters is observed in SSc patients. Adhesion molecules, including ...

CD70 is also selectively expressed in several ... company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T ) products for cancer and autoimmune disease.